<?xml version="1.0"?><root><issue><title Title="Issue xml" direction="ltr">International Journal of Endocrinology and Metabolism</title><title_fa Title="Title_fa">مجله‌ي بین المللی غدد درون‌ريز و متابوليسم</title_fa><short_title Title="Short_title">Int J Endocrinol Metab</short_title><subject Title="Subject">Medical Sciences</subject><web_url Title="Web_url">http://www.ijem.org</web_url><journal_hbi_system_id Title="Journal_hbi_system_id"></journal_hbi_system_id><journal_hbi_system_user Title="Journal_hbi_system_user"></journal_hbi_system_user><journal_id_issn Title="Journal_id_issn">1726-913X</journal_id_issn><journal_id_issn_online Title="Journal_id_issn_online"></journal_id_issn_online><journal_id_pii Title="Journal_id_pii"></journal_id_pii><journal_id_doi Title="Journal_id_doi"></journal_id_doi><journal_id_iranmedex Title="Journal_id_iranmedex"></journal_id_iranmedex><journal_id_magiran Title="Journal_id_magiran"></journal_id_magiran><journal_id_sid Title="Journal_id_sid"></journal_id_sid><journal_id_nlai Title="Journal_id_nlai"></journal_id_nlai><journal_id_science Title="Journal_id_science"></journal_id_science><language Title="Language">en</language><article><article_id_issn_online Title="Article_id_issn_online"></article_id_issn_online><article_id_pubmed Title="Article_id_pubmed"></article_id_pubmed><article_id_pii Title="Article_id_pii"></article_id_pii><article_id_doi Title="Article_id_doi"></article_id_doi><article_id_iranmedex Title="Article_id_iranmedex"></article_id_iranmedex><article_id_magiran Title="Article_id_magiran"></article_id_magiran><article_id_sid Title="Article_id_sid"></article_id_sid><articletitle Title="ArticleTitle">Treatment of Idiopathic Short Stature with Growth Hormone</articletitle><authors Title="Authors">Sadeghi-Nejad Ab<author><full_name>Sadeghi-Nejad Ab</full_name><suffix /><email /><code /><affiliation /></author></authors><articleinstitution Title="ArticleInstitution">Department of Pediatrics, Tufts University School of Medicine , Division of Pediatric Endocrinology and Metabolism, Floating Hospital for Children, Tufts Medical Center, Boston, Massachusetts, 02111, </articleinstitution><articlecategory Title="ArticleCategory">Editorial</articlecategory><articleabstract Title="ArticleAbstract">--</articleabstract><articlekeyword Title="ArticleKeyword">--</articlekeyword><articleruningtitle Title="ArticleRuningTitle">Growth Hormone therapy of idiopathic short stature</articleruningtitle><articlecorrespondence Title="ArticleCorrespondence"> A. Sadeghi-Nejad</articlecorrespondence><articlereceivedate Title="ArticleReceiveDate">11/8/2008 12:00:00 AM</articlereceivedate><articleaccepteddate TitlePe="ArticleAcceptedDate">12/15/2008 12:00:00 AM</articleaccepteddate><articleemail Title="ArticleEmail">asadeghi@tuftsmedicalcenter.org</articleemail><articleissuenumber Title="ArticleIssueNumber">4</articleissuenumber><articlestartpage Title="ArticleStartPage">159</articlestartpage><articleendpage Title="ArticleEndPage">161</articleendpage><artweb_url Title="Artweb_url">http://www.ijem.org/Default.aspx</artweb_url></article><articlevolumenumber Title="ArticleVolumeNumber">6</articlevolumenumber><article><article_id_issn_online Title="Article_id_issn_online"></article_id_issn_online><article_id_pubmed Title="Article_id_pubmed"></article_id_pubmed><article_id_pii Title="Article_id_pii"></article_id_pii><article_id_doi Title="Article_id_doi"></article_id_doi><article_id_iranmedex Title="Article_id_iranmedex"></article_id_iranmedex><article_id_magiran Title="Article_id_magiran"></article_id_magiran><article_id_sid Title="Article_id_sid"></article_id_sid><articletitle Title="ArticleTitle">The Effect of Pioglitazone on Adiposity, Adiponectin and Carotid Artery Intimal Thickness in Obese but Otherwise Healthy Minority Subjects</articletitle><authors Title="Authors">Salehian B, Bilas J, Mahabadi V, Aleli V, Norris K, Bhasin SH <author><full_name>Salehian B</full_name><suffix /><email /><code /><affiliation /></author><author><full_name> Bilas J</full_name><suffix /><email /><code /><affiliation /></author><author><full_name> Mahabadi V</full_name><suffix /><email /><code /><affiliation /></author><author><full_name> Aleli V</full_name><suffix /><email /><code /><affiliation /></author><author><full_name> Norris K</full_name><suffix /><email /><code /><affiliation /></author><author><full_name> Bhasin SH </full_name><suffix /><email /><code /><affiliation /></author></authors><articleinstitution Title="ArticleInstitution">Division of Endocrinology, Metabolism and Molecular Medicine, Charles R Drew University of Medicine and Science, Los Angeles, CA</articleinstitution><articlecategory Title="ArticleCategory">Original Article</articlecategory><articleabstract Title="ArticleAbstract">We examined the hypothesis that the PPAR Gamma activator, Pioglitazone, has a fat depot specific effect and aimed at determining the ef-fects of pioglitazone on changes in total and re-gional fat distribution, serum adiponectin levels, carotid artery intimal thickness, and subcutane-ous adipose tissue histology in otherwise healthy obese men and women from a minority popu-lation. 
Materials and Methods: This is a double-blind, randomized, controlled trial, single site study of the minority population in south central Los Angeles. Thirty-five obese, but otherwise healthy, men and women (waist-to-hip ratio &amp;gt;0.95 for men and &amp;gt;0.85 in women) were ran-domly assigned into three groups: Group A: pla-cebo; group B, pioglitazone 30 mg/day, and group C, pioglitazone 45 mg/day, for a duration of 6 months. The primary outcome measures were changes in visceral fat as measured by Computerized Tomography scan (CT Scan) of the abdomen and thigh, body composition by Dual energy X-ray Absorptiometry Scan (DXA scan) and carotid artery intima-media thickness as measured by ultrasound. Serum adiponectin levels and the size and number of adipocytes were also measured.
Results: At baseline, mean age, proportion of female participation, race and ethnicity distribu-tion, blood pressure, Body Mass Index (BMI) and anthropometric measures of subjects in the three groups were not statistically different. After 6 months, we observed significant decrease of intramuscular fat and significant increase of subcutaneous thigh fat in groups B and C as compared to group A. The average carotid artery intimal thickness increased in group A (p&amp;lt;0.01), but not in group B, and decreased in group C (p&amp;lt;0.01). Serum adiponectin levels rose sharply (p&amp;lt;0.001) in the treatment groups only. A signifi-cant positive correlation was observed between the change of the adiponectin levels and subcu-taneous thigh fat. 
Conclusion: Results of this study supports the use of pioglitazone in the prevention of stroke and peripheral vascular disease in high-risk populations.</articleabstract><articlekeyword Title="ArticleKeyword">Pioglitazone, Subcutaneous fat, Visceral fat, Carotid artery, Intimal thickness, Adiponectin, Adipose tissue</articlekeyword><articleruningtitle Title="ArticleRuningTitle">Politazone, Adiponectin and CAIT </articleruningtitle><articlecorrespondence Title="ArticleCorrespondence">Behrouz Salehian</articlecorrespondence><articlereceivedate Title="ArticleReceiveDate">7/16/2008 12:00:00 AM</articlereceivedate><articleaccepteddate TitlePe="ArticleAcceptedDate">11/23/2008 12:00:00 AM</articleaccepteddate><articleemail Title="ArticleEmail">bsalehian@coh.org</articleemail><articleissuenumber Title="ArticleIssueNumber">4</articleissuenumber><articlestartpage Title="ArticleStartPage">162</articlestartpage><articleendpage Title="ArticleEndPage">174</articleendpage><artweb_url Title="Artweb_url">http://www.ijem.org/Default.aspx</artweb_url></article><articlevolumenumber Title="ArticleVolumeNumber">6</articlevolumenumber><article><article_id_issn_online Title="Article_id_issn_online"></article_id_issn_online><article_id_pubmed Title="Article_id_pubmed"></article_id_pubmed><article_id_pii Title="Article_id_pii"></article_id_pii><article_id_doi Title="Article_id_doi"></article_id_doi><article_id_iranmedex Title="Article_id_iranmedex"></article_id_iranmedex><article_id_magiran Title="Article_id_magiran"></article_id_magiran><article_id_sid Title="Article_id_sid"></article_id_sid><articletitle Title="ArticleTitle">Lipids, Apolipoproteins, Lipid Oxidation and Paraoxonase Enzyme Activity In Diabetic And Non-Diabetic End Stage Renal Disease Patients</articletitle><authors Title="Authors">Solati M, Raiszadeh F, Azizi F<author><full_name>Solati M</full_name><suffix /><email /><code /><affiliation /></author><author><full_name> Raiszadeh F</full_name><suffix /><email /><code /><affiliation /></author><author><full_name> Azizi F</full_name><suffix /><email /><code /><affiliation /></author></authors><articleinstitution Title="ArticleInstitution">Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University (MC), Tehran, I.R. Iran </articleinstitution><articlecategory Title="ArticleCategory">Original Article</articlecategory><articleabstract Title="ArticleAbstract">Paraoxonase (PON) is a serum esterase, asso-ciated with HDL-C. It decreases the oxidation of LDL-C. Serum PON1 activity has been shown to diminish in several diseases. We investigated the serum PON1 activity and lipid profiles in di-abetic and non-diabetic end stage renal disease (ESRD) patients and controls as well as serum PON1 activity pre and post dialysis.
Materials and Methods: For this study we re-cruited 92 patients with ESRD on hemodialysis, and 46 healthy controls. The patients were as-signed into diabetic and non-diabetic groups (each, n=46 each). Serum lipid profiles including total cholesterol, triglycerides, HDL-C, apolipo-protein A-1, apolipoprotein B, Lipoprotein (a) se-rum PON activity, oxidized LDL-C and total an-tioxidant capacity were compared among groups. Furthermore, pre and post dialysis serum PON activity were also compared.
Results: Serum levels of total cholesterol, HDL-C, LDL-C and apoA-I were lower in the ESRD patients, compared to controls. While serum PON activity was significantly lower in the ESRD than in controls, it did not differ significantly between diabetic and non-diabetic patients with ESRD. Serum PON activity was observed to rise significantly postdialysis, compared to predialysis, 69&amp;#177;48 vs. 72&amp;#177;50 IU/ml and 47&amp;#177;32 vs. 53&amp;#177;37 IU/ml in diabetic and non- diabetic patients respectively, the increase being significantly correlated with the quality of hemoidalysis.
Conclusion: To conclude, reduced serum pa-raoxonase activity in diabetes and non-diabetes ESRD may further predispose lipids to oxida-tion. Enhancement of the quality of hemodialysis can increase serum PON activity in hemodialysis patients.</articleabstract><articlekeyword Title="ArticleKeyword">Paraoxonase, Lipoproteins, Apolipoproteins, Diabetes, End Stage Renal Disease, Oxidized LDL-C</articlekeyword><articleruningtitle Title="ArticleRuningTitle">Paraoxonase and End Stage Renal Disease</articleruningtitle><articlecorrespondence Title="ArticleCorrespondence">Fereidoun Azizi</articlecorrespondence><articlereceivedate Title="ArticleReceiveDate">9/20/2008 12:00:00 AM</articlereceivedate><articleaccepteddate TitlePe="ArticleAcceptedDate">11/8/2008 12:00:00 AM</articleaccepteddate><articleemail Title="ArticleEmail">azizi@endocrine.ac.ir</articleemail><articleissuenumber Title="ArticleIssueNumber">4</articleissuenumber><articlestartpage Title="ArticleStartPage">175</articlestartpage><articleendpage Title="ArticleEndPage">182</articleendpage><artweb_url Title="Artweb_url">http://www.ijem.org/Default.aspx</artweb_url></article><articlevolumenumber Title="ArticleVolumeNumber">6</articlevolumenumber><article><article_id_issn_online Title="Article_id_issn_online"></article_id_issn_online><article_id_pubmed Title="Article_id_pubmed"></article_id_pubmed><article_id_pii Title="Article_id_pii"></article_id_pii><article_id_doi Title="Article_id_doi"></article_id_doi><article_id_iranmedex Title="Article_id_iranmedex"></article_id_iranmedex><article_id_magiran Title="Article_id_magiran"></article_id_magiran><article_id_sid Title="Article_id_sid"></article_id_sid><articletitle Title="ArticleTitle">Serum Resistin Concentration in Obese Diabetic patients: Any Possible Relation to Insulin Resistance Indices?


</articletitle><authors Title="Authors">Mohammadzadeh G, Zarghami N, Mobaseri M<author><full_name>Mohammadzadeh G</full_name><suffix /><email /><code /><affiliation /></author><author><full_name> Zarghami N</full_name><suffix /><email /><code /><affiliation /></author><author><full_name> Mobaseri M</full_name><suffix /><email /><code /><affiliation /></author></authors><articleinstitution Title="ArticleInstitution">Nutritional Research Center, &amp; Department of Clinical Biochemistry and RIA, Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran, Endocrinology and Metabolism Research Cen</articleinstitution><articlecategory Title="ArticleCategory">Original Article</articlecategory><articleabstract Title="ArticleAbstract">Resistin, an adipocyte secreted hormone, has been suggested to link obesity with type 2 di-abetes and insulin resistance in rodent models, but its relevance to human diabetes remains un-certain. The aim of this study was to investigate the relationship between serum resistin concen-trations with markers of insulin resistance and obesity in type 2 diabetes and non-diabetic obese subjects.
Materials and Methods: In this cross sectional study, consisting of 35 obese subjects with type 2 diabetes (16 women and 19 men, age 44.63±1.08 yr) and 35 obese non-diabetic subjects (19 women and 16 men, age 43.54±1.54 yr), fasting lipid profiles were measured by enzymatic methods; NycoCard HbA1c system was used to measure HbA1c. Serum resistin, insulin and glucose levels were measured by an enzyme immunoassay, and glucose oxidase methods respectively. Insulin resistance index was calculated from fasting glucose and insulin according to homeostasis model assessment (HOMA-IR). 
Results: Mean insulin resistance index (HOMA-IR), HbA1c, diastolic blood pressure, triglyce-rides and fasting glucose in diabetics were sig-nificantly higher than in non-diabetic subjects (p&lt;0.05). There was no significant difference in resistin levels between non-diabetic (7.16±3.72 ng/ml) and diabetic (6.40±3.66 ng/ml) obese sub-jects. Resistin levels in diabetic (7.46±3.98 vs. 5.51± 3.20 ng/mL) and non-diabetic (8.15±4.60 vs. 5.97±2.31 ng/mL) women were significantly higher than men in both groups. A significant negative correlation between diastolic blood pressure and resistin (r= -0.381; p=0.024) was ob-served only in the control groups.
Conclusion: Based on the results, it appears that resistin links between obesity and type II di-abetes in humans is still a controversial topic and requires further investigation.
</articleabstract><articlekeyword Title="ArticleKeyword">Type 2 diabetes, Obesity, Resistin, HOMA-IR, BMI</articlekeyword><articleruningtitle Title="ArticleRuningTitle">Serum resistin of obese diabetics</articleruningtitle><articlecorrespondence Title="ArticleCorrespondence">Dr. Nosratollah Zarghami</articlecorrespondence><articlereceivedate Title="ArticleReceiveDate">11/23/2008 12:00:00 AM</articlereceivedate><articleaccepteddate TitlePe="ArticleAcceptedDate">12/13/2008 12:00:00 AM</articleaccepteddate><articleemail Title="ArticleEmail">Zarghami@tbzmed.ac.ir</articleemail><articleissuenumber Title="ArticleIssueNumber">4</articleissuenumber><articlestartpage Title="ArticleStartPage">183</articlestartpage><articleendpage Title="ArticleEndPage">193</articleendpage><artweb_url Title="Artweb_url">http://www.ijem.org/Default.aspx</artweb_url></article><articlevolumenumber Title="ArticleVolumeNumber">6</articlevolumenumber><article><article_id_issn_online Title="Article_id_issn_online"></article_id_issn_online><article_id_pubmed Title="Article_id_pubmed"></article_id_pubmed><article_id_pii Title="Article_id_pii"></article_id_pii><article_id_doi Title="Article_id_doi"></article_id_doi><article_id_iranmedex Title="Article_id_iranmedex"></article_id_iranmedex><article_id_magiran Title="Article_id_magiran"></article_id_magiran><article_id_sid Title="Article_id_sid"></article_id_sid><articletitle Title="ArticleTitle">Relationship Between Serum Leptin and Adiponectin and Bone Mass with Energy Intake and Nutrients in 40-60 Year-Old Postmenopausal Women</articletitle><authors Title="Authors">Mottaghi A, Jazayery A, Golestan B<author><full_name>Mottaghi A</full_name><suffix /><email /><code /><affiliation /></author><author><full_name> Jazayery A</full_name><suffix /><email /><code /><affiliation /></author><author><full_name> Golestan B</full_name><suffix /><email /><code /><affiliation /></author></authors><articleinstitution Title="ArticleInstitution">Faculty of Public Health, Tehran University of Medical Sciences; Tehran, I.R.Iran</articleinstitution><articlecategory Title="ArticleCategory">Original Article</articlecategory><articleabstract Title="ArticleAbstract">Adequate nutrition is crucial for growth and maintenance of the body skeleton health; nu-trients consumed affect leptin and adiponectin levels and bone mass. This study was done to determine the relationship between serum leptin, adiponectin and bone mass with energy intake and nutrients in postmenopausal women, 40-60 years old. 
Material and Methods: The present cross-sectional study was done on 85 postmenopausal women, aged 40-60 years. Samples of fasting blood were taken to determine serum concentra-tions of leptin and adiponectin and bone mineral density was measured by the DXA method in the two areas of L2-4 and the femoral neck. Food intake was documented using questionnaires in-cluding food frequency and data was analyzed by FP2 software. 
Results: Leptin had a negative relationship with energy intake, protein and magnesium and a positive relationship with carbohydrate; there was a positive relationship between adiponectin and energy and carbohydrate intakes. BMD of femur had a negative relationship with energy and carbohydrate, while it had positive relation-ship with calcium, and there was direct and sig-nificant relationship between BMD of the spine and zinc intake.
Conclusion: Increase in consumption of carbo-hydrates and decrease in consumption of protein led to increase in leptin levels. Consumption of calcium and zinc can have a protective effect on bones.</articleabstract><articlekeyword Title="ArticleKeyword">Leptin, Adiponectin, Bone mass, Nutrients</articlekeyword><articleruningtitle Title="ArticleRuningTitle">Serum leptin, adiponectin and bone mass </articleruningtitle><articlecorrespondence Title="ArticleCorrespondence">Azadeh Motaghi</articlecorrespondence><articlereceivedate Title="ArticleReceiveDate">10/13/2008 12:00:00 AM</articlereceivedate><articleaccepteddate TitlePe="ArticleAcceptedDate">11/20/2008 12:00:00 AM</articleaccepteddate><articleemail Title="ArticleEmail">mottaghi_a@razi.tums.ac.ir</articleemail><articleissuenumber Title="ArticleIssueNumber">4</articleissuenumber><articlestartpage Title="ArticleStartPage">194</articlestartpage><articleendpage Title="ArticleEndPage">199</articleendpage><artweb_url Title="Artweb_url">http://www.ijem.org/Default.aspx</artweb_url></article><articlevolumenumber Title="ArticleVolumeNumber">6</articlevolumenumber><article><article_id_issn_online Title="Article_id_issn_online"></article_id_issn_online><article_id_pubmed Title="Article_id_pubmed"></article_id_pubmed><article_id_pii Title="Article_id_pii"></article_id_pii><article_id_doi Title="Article_id_doi"></article_id_doi><article_id_iranmedex Title="Article_id_iranmedex"></article_id_iranmedex><article_id_magiran Title="Article_id_magiran"></article_id_magiran><article_id_sid Title="Article_id_sid"></article_id_sid><articletitle Title="ArticleTitle">Glycemic Index of Various Brands of Rice in Healthy Individuals</articletitle><authors Title="Authors">Zarrati M&lt;sup&gt;a&lt;/sup&gt;, Pirali M&lt;sup&gt;bc&lt;/sup&gt;, Mirmiran P&lt;sup&gt;c&lt;/sup&gt;, Noori N&lt;sup&gt;d&lt;/sup&gt;, Nakhoda K&lt;sup&gt;d&lt;/sup&gt;, Najafi H&lt;sup&gt;e&lt;/sup&gt;, Hoseini H&lt;sup&gt;b&lt;/sup&gt;
<author><full_name>Zarrati M&lt;sup&gt;a&lt;/sup&gt;</full_name><suffix /><email /><code /><affiliation /></author><author><full_name> Pirali M&lt;sup&gt;bc&lt;/sup&gt;</full_name><suffix /><email /><code /><affiliation /></author><author><full_name> Mirmiran P&lt;sup&gt;c&lt;/sup&gt;</full_name><suffix /><email /><code /><affiliation /></author><author><full_name> Noori N&lt;sup&gt;d&lt;/sup&gt;</full_name><suffix /><email /><code /><affiliation /></author><author><full_name> Nakhoda K&lt;sup&gt;d&lt;/sup&gt;</full_name><suffix /><email /><code /><affiliation /></author><author><full_name> Najafi H&lt;sup&gt;e&lt;/sup&gt;</full_name><suffix /><email /><code /><affiliation /></author><author><full_name> Hoseini H&lt;sup&gt;b&lt;/sup&gt;
</full_name><suffix /><email /><code /><affiliation /></author></authors><articleinstitution Title="ArticleInstitution">&lt;sup&gt;a&lt;/sup&gt; Nutrition Department, Ministry of Health and Medical Education, &lt;sup&gt;b&lt;/sup&gt; Department of Monitoring Food and Drugs, Tehran, &amp;amp; National Nutrition and Food Technology Research Institu</articleinstitution><articlecategory Title="ArticleCategory">Original Article</articlecategory><articleabstract Title="ArticleAbstract">Since the varying different contents of amylose in rice grains have different effects on blood sugar, we examined the effect of consumption of three varieties of rice on glucose response in healthy subjects, to compare the glycemic effects of 50 g carbohydrate in the Basmati, Kazemi and Sorna pearl varieties of rice in normal subjects.
Material and Methods: Thirty healthy subjects (13 males and 17 females), were evaluated 4 times at 1 week intervals. On the first day, all subjects consumed 50 g glucose, and were then divided into 3 groups. Each group consumed one of the 3 types of rice with 50 g carbohydrate con-tent each week. Blood samples were collected before and at 15, 30, 60 nd 120 minutes after tak-ing of glucose and rice consumption. The Gly-cemic index (GI) was calculated for each rice as the ratio of the incremental area under the 3-hour glycemic response curve to rice to the in-cremental area under the 3-hour glycemic re-sponse curve to 50 g glucose. 
Results: The GIs of Sorna pearl, Kazemi and Basmati were 52.2&amp;#177;5.1, 67.6&amp;#177;13 and 61.2&amp;#177;6.1 re-spectively, with that of Sorna pearl being lower than the others (p&amp;lt;0.05). Maximum changes in blood sugar for Sorna pearl, Kazemi and Basmati were 21.8&amp;#177;12, 27.4&amp;#177;6 and 31.7&amp;#177;5.9 mg/dL, respec-tively. 
Conclusion: Glycemic index and glycemic load for Sorna pearl rice were lower than for the other two rice types, difference statistically sig-nificant. The effect of Sorna pearl rice consumption in diabetes mellitus patients however needs more study.</articleabstract><articlekeyword Title="ArticleKeyword">Glycemic index, Glycemic load, Nutrient, Rice, Diabetics, Fasting blood sugar </articlekeyword><articleruningtitle Title="ArticleRuningTitle">Glycemic Index of Various Brands of Rice</articleruningtitle><articlecorrespondence Title="ArticleCorrespondence">Parvin Mirmiran</articlecorrespondence><articlereceivedate Title="ArticleReceiveDate">11/20/2008 12:00:00 AM</articlereceivedate><articleaccepteddate TitlePe="ArticleAcceptedDate">12/8/2008 12:00:00 AM</articleaccepteddate><articleemail Title="ArticleEmail">mirmiran@endocrine.ac.ir</articleemail><articleissuenumber Title="ArticleIssueNumber">4</articleissuenumber><articlestartpage Title="ArticleStartPage">200</articlestartpage><articleendpage Title="ArticleEndPage">204</articleendpage><artweb_url Title="Artweb_url">http://www.ijem.org/Default.aspx</artweb_url></article><articlevolumenumber Title="ArticleVolumeNumber">6</articlevolumenumber><article><article_id_issn_online Title="Article_id_issn_online"></article_id_issn_online><article_id_pubmed Title="Article_id_pubmed"></article_id_pubmed><article_id_pii Title="Article_id_pii"></article_id_pii><article_id_doi Title="Article_id_doi"></article_id_doi><article_id_iranmedex Title="Article_id_iranmedex"></article_id_iranmedex><article_id_magiran Title="Article_id_magiran"></article_id_magiran><article_id_sid Title="Article_id_sid"></article_id_sid><articletitle Title="ArticleTitle">Histological Diagnosis and Frequency of Primary Endocrine Tumors (ETs) and Neuroendocrine Tumors (NETs) According to WHO Classification</articletitle><authors Title="Authors">Bukhari MH&lt;sup&gt;a&lt;/sup&gt;, Niazi S&lt;sup&gt;a&lt;/sup&gt;, Shah N&lt;sup&gt;b&lt;/sup&gt;, Anwar M&lt;sup&gt;c&lt;/sup&gt;, Khalee EM&lt;sup&gt;a&lt;/sup&gt;, Samina Q, Munir M&lt;sup&gt;a&lt;/sup&gt;<author><full_name>Bukhari MH&lt;sup&gt;a&lt;/sup&gt;</full_name><suffix /><email /><code /><affiliation /></author><author><full_name> Niazi S&lt;sup&gt;a&lt;/sup&gt;</full_name><suffix /><email /><code /><affiliation /></author><author><full_name> Shah N&lt;sup&gt;b&lt;/sup&gt;</full_name><suffix /><email /><code /><affiliation /></author><author><full_name> Anwar M&lt;sup&gt;c&lt;/sup&gt;</full_name><suffix /><email /><code /><affiliation /></author><author><full_name> Khalee EM&lt;sup&gt;a&lt;/sup&gt;</full_name><suffix /><email /><code /><affiliation /></author><author><full_name> Samina Q</full_name><suffix /><email /><code /><affiliation /></author><author><full_name> Munir M&lt;sup&gt;a&lt;/sup&gt;</full_name><suffix /><email /><code /><affiliation /></author></authors><articleinstitution Title="ArticleInstitution">&lt;sup&gt;a&lt;/sup&gt;Department of Pathology King, Edward Medical University, Lahore, Pakistan; &lt;sup&gt;b&lt;/sup&gt; Department of Surgery, Mofftitt Cancer Center Tampa, Fl; &lt;sup&gt;c&lt;/sup&gt; Department of Epidemiology and</articleinstitution><articlecategory Title="ArticleCategory">Original Article</articlecategory><articleabstract Title="ArticleAbstract">The new WHO classification provides the foun-dation for tumor diagnosis, patient treatment and tools for clinico-epidemiological research. This study was conducted to determine the fre-quency and update the histological aspects of different endocrine and neuroenodocrine tumors for clinical significance and to minimize unclas-sified lesions.
Materials and Methods: Five hundred biopsies were analyzed in the Pathology Department of King Edward Medical University from 1st June 2004 to 31st December 2005. Tumors were diag-nosed with light microscopy using the new WHO classification. 
Results: Following 500 biopsies, 145 (29%) Endo-crine(ET) and Neuroendocrine Tumors (NET) were found; majority of the former, ET, n=112 (77.2%), were in the thyroid, of which 84 (75%) were follicular adenomas and 28 (25%) were carcinomas, of the 28 carcinomas, the frequencies were: papillary carcinoma (PC) 21 (75%); anaplastic(AC) 4 (14.28%); follicular(FC) 2 (7.14%); and medullary (MC) 1 (3.57%). Of the 145, 33 (22.8%) were neuroendocrine tumors (NET), with the following types and frequencies: adrenal 13 (39.5%); pituitary 10 (30.5%); pancreatic 4 (12%); parathyroid 3(9%); appendix 1 (3%); and rectum 1 (3%). One NET detected in the thyroid region was a well-differentiated neuroendocrine carcinoma (WDNEC). Among adrenal NETs, of 13 only 2 (14.4%) were malignant and diagnosed as a cortical and a neuroblastoma respectively, while all others were benign NETS, as follows: cortical adenoma 2 (15.38%); pheochromocytoma 7 (53.8%) and 1 (7.69%) ganglio neuroblastoma, and ganglioneuroma each respectively. All pituitary, parathyroid and pancreatic NETS were benign in nature. NETS of the appendix and rectum were WDNETS, while that of the lung was a WDNEC.
Findings of this study confirm that the WHO classification provides uniform, simple, repro-ducible and practical criteria for diagnosis of ETs and NETS.</articleabstract><articlekeyword Title="ArticleKeyword">Endocrine tumors, Neuroendocrine tumors, Histological classification</articlekeyword><articleruningtitle Title="ArticleRuningTitle">Histological Diagnosis of Endocrine Tumors</articleruningtitle><articlecorrespondence Title="ArticleCorrespondence">Mulazim Hussain Bukhari</articlecorrespondence><articlereceivedate Title="ArticleReceiveDate">9/28/2008 12:00:00 AM</articlereceivedate><articleaccepteddate TitlePe="ArticleAcceptedDate">11/4/2008 12:00:00 AM</articleaccepteddate><articleemail Title="ArticleEmail">drmhbukhari@yahoo.com</articleemail><articleissuenumber Title="ArticleIssueNumber">4</articleissuenumber><articlestartpage Title="ArticleStartPage">205</articlestartpage><articleendpage Title="ArticleEndPage">214</articleendpage><artweb_url Title="Artweb_url">http://www.ijem.org/Default.aspx</artweb_url></article><articlevolumenumber Title="ArticleVolumeNumber">6</articlevolumenumber><article><article_id_issn_online Title="Article_id_issn_online"></article_id_issn_online><article_id_pubmed Title="Article_id_pubmed"></article_id_pubmed><article_id_pii Title="Article_id_pii"></article_id_pii><article_id_doi Title="Article_id_doi"></article_id_doi><article_id_iranmedex Title="Article_id_iranmedex"></article_id_iranmedex><article_id_magiran Title="Article_id_magiran"></article_id_magiran><article_id_sid Title="Article_id_sid"></article_id_sid><articletitle Title="ArticleTitle">Interaction Between Testosterone and Bicuculline GABAA Antagonist in the CA1 Region of Hippocampus in Spatial Learning in Adult Male Rats</articletitle><authors Title="Authors">Gholaminejad A&lt;sup&gt;a&lt;/sup&gt;, Naghdi N&lt;sup&gt;a&lt;/sup&gt;, Soleimannejad E&lt;sup&gt;a&lt;/sup&gt;, Vaezi Gh&lt;sup&gt;b&lt;/sup&gt;<author><full_name>Gholaminejad A&lt;sup&gt;a&lt;/sup&gt;</full_name><suffix /><email /><code /><affiliation /></author><author><full_name> Naghdi N&lt;sup&gt;a&lt;/sup&gt;</full_name><suffix /><email /><code /><affiliation /></author><author><full_name> Soleimannejad E&lt;sup&gt;a&lt;/sup&gt;</full_name><suffix /><email /><code /><affiliation /></author><author><full_name> Vaezi Gh&lt;sup&gt;b&lt;/sup&gt;</full_name><suffix /><email /><code /><affiliation /></author></authors><articleinstitution Title="ArticleInstitution">&lt;sup&gt;a&lt;/sup&gt;Department of Physiology, Pasteur Institute of Iran, 13164 Tehran, &lt;sup&gt;b &lt;/sup&gt;Department of Physiology, Damghan Branch, Islamic Azad University, Damghan, IR. Iran</articleinstitution><articlecategory Title="ArticleCategory">Original Article</articlecategory><articleabstract Title="ArticleAbstract">The hippocampus plays a vital role in spatial learning and memory. Testosterone appears to mediate spatial discrimination and the GABAer-gic system has also been reported to have a criti-cal role in this effect. In the present study we in-vestigated the interaction between testosterone (androgenic receptor agonist) and bicuculline (GABAA receptor antagonist) on spatial learning and memory performance in male Wistar rats. 
Materials and Methods: Cannulae were implanted into the CA1 of rats bilaterally and drugs were injected before daily training in the Morris water maze (MWM). In the first experiment, testosterone (0, 20, 40, 80 &amp;#181;g the 0.5 &amp;#181;l DMSO/side) was injected intra-CA1 before each session. In the second experiment, intra-CA1 injection of bicuculline (0, 1, 2, 4 &amp;#181;g 0.5 &amp;#181;l saline/side) were given before every session. In the last experiment, testosterone 80 &amp;#181;g, 0.5 &amp;#181;l and bicuculline 2 &amp;#181;g, 0.5 &amp;#181;l were injected into the CA1. 
Results: The results showed that testosterone 80 &amp;#181;g or bicuculline 2 &amp;#181;g, each given separately , and also microinjection of both testosterone + bicuculline increased travel distance and escape latency to find the platform, as compared to their vehicles. 
Conclusion: It is shown that administration of testosterone and bicuculline separately impaired spatial learning and memory. Microinjection of bicuculline after testosterone treatment did not change spatial learning impairment when com-pared to testosterone and bicuculline injected separately.</articleabstract><articlekeyword Title="ArticleKeyword">Hippocampus, Spatial learning and memory, Testosterone, Bicuculine, GABAA receptor, Morris Water Maze</articlekeyword><articleruningtitle Title="ArticleRuningTitle">Interaction Between Testosterone and GABAergic system in Hippocampus</articleruningtitle><articlecorrespondence Title="ArticleCorrespondence">Nasser Naghdi</articlecorrespondence><articlereceivedate Title="ArticleReceiveDate">11/18/2008 12:00:00 AM</articlereceivedate><articleaccepteddate TitlePe="ArticleAcceptedDate">12/14/2008 12:00:00 AM</articleaccepteddate><articleemail Title="ArticleEmail">naghdi@pasteur.ac.ir</articleemail><articleissuenumber Title="ArticleIssueNumber">4</articleissuenumber><articlestartpage Title="ArticleStartPage">215</articlestartpage><articleendpage Title="ArticleEndPage">225</articleendpage><artweb_url Title="Artweb_url">http://www.ijem.org/Default.aspx</artweb_url></article><articlevolumenumber Title="ArticleVolumeNumber">6</articlevolumenumber></issue></root>